CHEK1 and melanoma: Although the mechanisms by which Chk1 inhibitors boost BRAFi sensitivity in BRAFi-resistant melanoma still need further clarification, our results support a model that Chk1 inhibition in combination with BRAFi can lead melanoma cells to arrest improperly, enter into mitosis with highly damaged DNA, and undergo mitotic catastrophe/cell death (Figure 9).